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Pharmacodynamic models have been constructed to
describe the relationship between effect site levels and drug
effect. This process for a single drug is characterized
graphically using a sigmoidal concentration-effect curve
(Figure 1). The most important part of this curve is the steep
section that represents the dynamic range of drug effect. This
part charts the concentration-effect relationship from
baseline to maximal effect. Small changes in drug
concentration lead to large changes in drug effect within this
range. Similar changes made above or below this region only
produce minimal change in effect. These models can
therefore help avoid giving more drug than is needed to
achieve the desired effect.

Pharmacokinetics and pharmacodynamics
Both propofol and remifentanil have well established
population pharmacokinetic[1, 2]. Both models use a 3compartment model structure to predict plasma drug
concentrations over time. A fourth compartment is added to
account for the time lag between plasma and brain (effect
site) concentration. With these models, computers can
simulate the concentration versus time profile that results
from any combination of boluses and continuous infusions.
They also can account for differences in age and weight.

II. BACKGROUND

The optimization process will account for (i) the
pharmacokinetic behavior (distribution) of each drug, (ii) the
synergistic interaction between sedatives and analgesics, (iii)
the analgesic and sedative requirements for esophageal
instrumentation, (iv) the respiratory effects caused by these
drugs and (v) the mechanical capabilities and limitations of
the infusion pump delivery systems. A cost functional will
be developed to combine (scalarize) the multiple
optimization goals into a single objective optimization
problem.

sedatives and analgesics to allow esophageal instrumentation
while minimizing respiratory compromise and loss of
responsiveness in spontaneously breathing patients. The
control system will (i) minimize the time between the start of
administration of these intravenous anesthetics and when
there is sufficient analgesia to blunt a response to esophageal
instrumentation, (ii) minimize the duration of respiratory
compromise,
(iii)
minimize
the
duration
of
unresponsiveness, and (iv) minimize the time required for
full recovery once the intravenous anesthetics are terminated.
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Abstract- Modern anesthesia practice uses a combination of
drugs to manage pain and sedation. There are often adverse or
negative side effects that arise due to the same combination. A
control system will be designed that optimizes the delivery of
intravenous sedatives and analgesics to allow esophageal
instrumentation while minimizing respiratory compromise and
loss of responsiveness in spontaneously breathing patients. A
cost functional will be developed to combine the multiple
optimization goals into a single objective optimization problem.
It is not possible to simultaneously optimize all criteria. A
compromise solution must be selected. After selecting weighting
coefficients, simulations were run and evaluated by the
optimization function. The top five were plotted. The peaks for
the five selected doses look reasonable. The maintenance
infusions are probably too low for someone to tolerate a placed
probe. Additional work is needed to investigate this. These
results show promise for the development of a multiobjective
optimization approach to patient-specific selection of dosing
schemes.

I. INTRODUCTION
Modern anesthesia practice uses a combination of drugs
to manage pain and sedation. Two fast acting drugs –
propofol (sedative) and remifentanil (opioid) – are becoming
increasingly popular because of their rapid onset of effect,
ease of dose titration, and rapid elimination. Combining a
sedative and hypnotic drug often enhances the beneficial or
positive effects of both drugs. However, there are often
adverse or negative side effects that arise due to the same
combination. These include the cessation of spontaneous
breathing due to obstruction of the airway and/or loss of
respiratory drive (respiratory compromise) and loss of the
ability to communicate with the patient (loss of
responsiveness).
While anesthesiologists are trained to handle such
complications, these drugs are increasingly being used by
non-anesthesiologists in settings where the training and
equipment necessary to deal with these complications do not
exist. Procedures performed in these settings increase patient
risk. This paper will focus primarily on a common GI
procedure – placement of an ultrasound probe in the midesophagus (esophageal instrumentation).
Because most GI clinics do not have anesthesiologists
administering the drug(s), a system will be developed to
advise the clinician of an optimal dosing scheme that has
been adjusted specifically for each patient. A control system
will be designed that optimizes the delivery of intravenous
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Figure 1. An example of a single-drug pharmacodynamic model, loss of
responsiveness caused by propofol. This curve predicts the probability of a
given patient drawn from the sample population losing responsiveness at a
given propofol effect site concentration.

When two drugs are administered, their concentrationeffect curves can be combined into a 3D response surface
model. Response surface models consist of a set of
parameters that estimate the extent of drug interaction
(synergistic, antagonistic, or linear), the surface “slope”, and
the concentration of each drug alone that is required to
achieve a 50% probability of maximal effect.
Response surface models provide a three dimensional
visualization of combined drug effects (Fig 2) across various
dosing schemes. Response surfaces may be a useful tool in
identifying ideal concentration pairs that meet patient
analgesic needs yet avoid adverse effects, thereby improving
patient safety.

(1)

Control theory and drug delivery
Control systems often need to consider multiple
conflicting objectives in the pursuit of a real world optimal
solution. This can be expressed mathematically by the
simultaneous minimization of a set of objective functions, φk
and k=1,2,..,n where “n” is the number of objectives.
(equation 1).

p∈U

min (φ1 ( p ),φ2 ( p ),...,φn ( p ))

Variable vector “p” represents all simulated dosing
schemes and φk(p) the objective value to be optimized. The
control system attempts to simultaneously minimize all the
objective functions. Objectives of interest for drug delivery
during endoscopic procedures include:

minimize the time between the start of
administration of anesthetics and when there is
sufficient analgesia to blunt a response to
esophageal instrumentation,
minimize
the
duration
of
respiratory
compromise,
minimize the duration of unresponsiveness, and
minimize the time required for full recovery
once the anesthetics are terminated.

Figure 2. This surface shows rapid loss of responsiveness as propofol is
increased. Sevoflurane does not have as profound an effect on sedation,
shown by the very slow rise of the surface along the sevo axis. The solid line
about halfway up the surface slope represents the C50 isobol, or the
combination of drugs that would result in LOR in 50% of the population.

(i)

(ii)
(iii)
(iv)

For this study, the anesthetics are propofol and
remifentanil.
The variable vector for each the four
objectives include the amount of each drug that is delivered
as a bolus and as an infusion. Time is the variable to be
minimized in each objective.

1.

2.
3.

a priori – an aggregating function is used to
combine all objectives to a single value
(scalarization) using weighting coefficients,
priorities or goals prior to optimization
a posteriori – the Pareto-optimal set is presented to
a decision maker before any preference is made
progressive articulation – an iterative process
between the decision maker and optimizer is used to
approach a final solution.[3, 4]

Generally, no single solution exists that optimally
satisfies all objectives simultaneously. However, a set of
equally efficient (Pareto-optimal) solutions does exist. A
decision process is used to select a suitable compromise
solution from this set. The methods used to solve
multiobjective optimization problems fall into three general
classifications:
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III. METHODS
Clinical experience suggests that the depth of sedation
and analgesia required to blunt the response to esophageal
instrumentation through the oropharynx is significant and
often leads to a loss of responsiveness[5]. With the response
surface models for esophageal instrumentation, moderately
painful stimuli, respiratory compromise and loss of
responsiveness, we will explore through simulation the
ability of various dosing schemes to blunt the response to
esophageal instrumentation and once instrumented, be
quickly titrated to provide adequate analgesia and sedation
for a moderately painful stimulus while minimizing loss of
responsiveness. We hypothesized that dosing schemes exists
to meet these clinical goals.
An approach to establishing a clinically relevant
weighting scheme for each objective is to consult a panel of
experts (i.e. board certified anesthesiologists). In anesthesia,
expert opinion has been used to develop a set of consensus
statements that can be used to will be asked to develop
consensus statements that prioritize the objectives using a
modified Delphi technique. Weighting coefficients will be
based on their objective prioritization.
Previous work has developed response surface models of
propofol and remifentanil for loss of response to esophageal
instrumentation[6], loss of responsiveness[7], sedation[8],
respiratory compromise[9] and tibial pressure[8] (see Table 1
and equation 2). The iso-effect lines representing 95%
probability of no response for each criterion, with the
exception of respiratory compromise, which will use 50%
probability, will be combined to identify ideal target
remifentanil-propofol concentration pairs that allow
esophageal instrumentation yet minimize unwanted
respiratory compromise or loss of responsiveness. The
response surface models will be used to define boundary
conditions for a series of optimization targets. Clinical goals
will be used to construct a cost functional.
A series of simulations will be conducted across a range of
bolus sizes (Prop: 0-2.67 mg/kg, Remi: 0-6.67 mcg/kg) and
infusion rates (Prop: 10-150 mcg/kg/min, Remi: 0-0.375
mcg/kg/min) to identify ideal dosing regimens and minimize
the cost functional. All simulations will be run for a 55 year
old, 75 kg, 175 cm male. Dosing regimens will be optimized
in terms of the ratio of propofol to remifentanil, bolus
dosing, and infusion rates, and time to reach or spent above
each isobole.

(2)

8.8

5.4

12.5

33.1

27. 8

Remi C50

4.2

2.8

1.8

2.2

4.0

Prop C50

8.2

2.9

5.1

3.6

20.1

Alpha

8.3

6.0

3.8

5

3.4

n

Table 1. Greco model parameters for pharmacodynamic effects used for
optimizing dose selection. Remi C50 is in ng/mL while prop C50 is in
mcg/mL. Alpha and n are unitless. These parameters can be combined with
equation 2 to determine the probability of no response to the associated
effect at a given remifentanil:propofol concentration pair.
Model
Esophageal
Instrumentation
Loss of
Responsiveness
Sedation
Respiratory
Compromise
Analgesia
(30 psi)

n

k =1

min ∑ wk φ k ( p )
p∈U

(3)

This study will follow the “a priori” approach to
converge on an optimal dosing scheme for a given patient
demographic. Weighting coefficients (wk) will be used to
adjust how much influence each objective has in the
aggregate objective function (equation 3).

IV. RESULTS
It is not possible to simultaneously optimize all criteria. A
compromise solution must be selected. For this paper we
were not able to obtain weight coefficients (wk) using the
modified Delphi technique as mentioned in the methods. To
obtain preliminary results, the weights listed in Table 2 were
used.
In the first iteration, the objective function was selecting
runs where the patient would not have tolerated esophageal
instrumentation, evidenced by having negative times for
criteria 1. Obviously, the procedure cannot occur if the probe
is not inserted. Therefore, this target must be converted to a
constraint – it absolutely must be reached.

1
2
3
4
5
6
7

k

Time to 95% Esophageal Instrumentation
Time above 95% Esophageal Instrumentation
[Time to 50% Respiratory Compromise]-1
Time above 50% Respiratory Compromise
Time above 95% 30 psi
Time above 95% Loss of Responsiveness
Time to 5% Sedation

Criteria

0.3
0.05
0.1
0.3
0.05
0.1
0.1

wk

Table 2. A list of the multiple objectives the aggregating function is taking
into consideration. Weighting coefficients are shown in the third column.
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Criteria
>0
>1

Constraint

Table 3. Constraints added to multiobjective optimization to ensure the
results will lead to successful procedures.

Time to 95% Esophageal Instrumentation
Time to 5% Sedation
In the second iteration it was noticed that the new “top”
simulations were not keeping patients sufficiently
anesthetized after probe insertion for them to tolerate the
procedure. In other words, the patient would be able to
tolerate placement of the probe but drug levels would soon
drop, causing them to respond to the placed probe. This was
evident by having negative times for criteria 7 (see Table 2).
Correcting this required an additional constraint for wakeup
time. Constraints are listed in Table 3.
Following these modifications, the 6,615 simulated dosing
strategies were sorted by their aggregate objective function
output (score). The top five results are shown in Table 4 as
well as Figure 3.

Bolus
mg/kg
20
20
20
20
20

Infusion
mcg/kg/min
0.0125
0.01
0.02
0.015
0.0225

Bolus
mg/kg
0.5
0.47
0.67
0.6
0.75

Infusion
mcg/kg/min

Remifentanil

0.8
0.93
0.67
0.8
0.67

Propofol

Table 4a. Dosing information for the top 5 simulations selected by the
aggregating objective function. (score).
Score
2.91
2.98
2.99
3.06
3.12

1.83
1.50
1.67
1.50
1.50

1

0.33
1.33
0.83
1.33
1.33

2

1.50
1.50
1.50
1.50
1.50

5.83
6.00
6.17
6.17
6.50

3.83
4.00
4.00
4.17
4.33

1.83
2.67
1.17
2.17
1.33

0.67
0.50
1.33
1.17
1.50

Table 4b. Times (in minutes) used by the aggregating objective function
to determine a score for each simulation.
Criteria # (from Table 2)
3
4
5
6
7
Score

2.91
2.98
2.99
3.06
3.12

V. DISCUSSION
The peaks for the five selected doses look reasonable.
However, there might not be enough time above the
esophageal instrumentation isobole (EI) to ensure the
clinician has sufficient time to place the probe. This
constraint can easily be modified to select just those doses
that are above the 95% esophageal instrumentation isobole
for some minimum amount of time.
A second concern is that the maintenance infusion (the
effect site concentration that remains once the bolus effect
has worn off) is still probably too low for someone to
tolerate a placed probe. However, additional data collection

Figure 3. Plot showing the isoboles representing our optimization
targets as well as plots of the top 5 dosing simulations as determined by
the aggregating objective function. Markers represent whole minutes.
The bolus dose causes the peak while the infusion holds the subject at a
steady concentration for the duration of the procedure (dark lines just
above Sed isobole). Text boxes show the score of the associated plot.

is necessary to determine what the minimum effect site
concentration must be for patients to not respond to a placed
probe. Once this isobole is built, an additional constraint can
be added to the aggregating objective function, ensuring that
the selected dosing schemes do not fall below this target.
Another possible solution is to establish a minimum
infusion rate. As seen in Table 4a, the doses currently being
selected have a propofol infusion rate of 20 mcg/kg/min.
Adding a constraint requiring a minimum of, for example, 50
mcg/kg/min could yield the same result without requiring
additional data collection. It would still be necessary to
determine the minimum rate necessary to ensure patients do
not respond.
A preliminary look at this approach was taken. The results
for the top five simulations selected by the aggregating
objective function are shown in Table 5 and Figure 4.
Immediately obvious is that the bolus sizes are larger, as are
the propofol infusion rates. However, the remifentanil
infusion rates are significantly lower. The times for criteria 6
and 7 are also higher than those listed in Table 4b. However,
since higher infusion rates are used, it is expected that it will
take longer for the drug effects to wear off.
In comparing Figures 3 and 4, it is interesting that this
time the aggregating objective function selected dosings with
significantly lower remifentanil concentrations as well as
significantly higher bolus sizes. Additional work will
investigate this, potentially modifying the weighting
coefficients to place more emphasis on effects produced by
remifentanil.
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Bolus
mg/kg
50
50
50
60
50

Infusion
mcg/kg/min
0.3
0.18
0.2
0.17
0.3

Bolus
mg/kg
0.0125
0.00625
0.00625
0.0075
0

Infusion
mcg/kg/min

Remifentanil

1.2
1.47
1.6
1.33
1.2

Propofol

Table 5a. Dosing information for the top 5 simulations selected by the
aggregating objective function (score) after a constraint has been added
requiring a minimum propofol infusion rate of 50 mcg/kg/min. The bolus
sizes are larger, as are the propofol infusion rates. However, the
remifentanil infusion rates are significantly lower.
Score
4.19
4.21
4.36
4.37
4.39

1.33
1.50
1.17
2.00
1.83

1
1.83
1.50
2.17
0.17
0.33

2
8.00
7.67
8.17
7.83
7.67

4.67
4.33
4.67
4.17
3.83

Criteria # (from Table 2)
3
4
5
1.50
2.00
2.00
1.50
2.00

4.00
4.50
4.83
4.33
5.67

6
5.17
5.17
5.33
6.17
5.67

7

Table 5b. Times (in minutes) used by the aggregating objective function
to determine a score for each simulation. The times for criteria 6 and 7
are generally higher than those in Table 4b, a natural result of using
higher infusion rates.
Score
4.19
4.21
4.36
4.37
4.39

Figure 4. Plot showing the isoboles representing our optimization
targets as well as plots of the top 5 dosing simulations as determined by
the aggregating objective function once a constraint requiring a
minimum propofol infusion rate of 50 mcg/kg/min has been added.
Markers represent whole minutes. There are three simulations
overlapping on the middle plot. Their peaks occur at the center of the
text box showing their score. Notice the changed Y-axis scale as well.

VI. CONCLUSION
These results show promise for the development of a
multiobjective optimization approach to patient-specific
selection of dosing schemes. Additional work is needed to
determine appropriate weighting coefficients and constraints.
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